search
Back to results

"ALCO-VR": Virtual Reality Cue Exposure Therapy for the Treatment of Alcohol Use Disorder

Primary Purpose

Alcohol Use Disorder

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Virtual Reality Cue Exposure Therapy
Treatment-as-usual
Sponsored by
University of Barcelona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Use Disorder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with moderate (4-5 diagnostic criteria) or severe (6 or more diagnostic criteria) AUD according to DSM-5
  • Minimum 3 days abstinence before initial evaluation

Exclusion Criteria:

  • severe cognitive impairment that could interfere with comprehension and completion of the task
  • severe psychopathology (e.g. major depression, schizophrenia, dementia)
  • opiate addiction
  • epilepsy
  • severe visual impairments
  • pregnancy

Sites / Locations

  • Universitat de Barcelona

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment-as-usual supplemented with virtual reality cue-exposure therapy

Treatment-as-usual

Arm Description

Treatment-as-usual supplemented with virtual reality cue-exposure therapy (TAU + VR-CET).

Only treatment-as-usual (TAU)

Outcomes

Primary Outcome Measures

Change in Craving based on AUDIT
Change in Craving levels using the Alcohol Use Disorders Identification Test (AUDIT), with scores ranging from 0 to 40. Higher scores reflect higher levels of craving
Change in Craving based on MACS
Change in Craving levels using the Multidimensional Alcohol Craving Scale (MACS), with scores ranging from 0 to 60. Higher scores reflect higher levels of craving
Change in Anxiety
Change in Anxiety levels using the State-Trait Anxiety Inventory (STAI), with scores ranging from 0 to 60. Higher scores reflect higher levels of anxiety

Secondary Outcome Measures

Full Information

First Posted
April 12, 2021
Last Updated
April 19, 2023
Sponsor
University of Barcelona
Collaborators
Hospital Clinic of Barcelona, Ministry of Health, Spain, Agència de Gestió d'Ajuts Universitaris i de Recerca
search

1. Study Identification

Unique Protocol Identification Number
NCT04858061
Brief Title
"ALCO-VR": Virtual Reality Cue Exposure Therapy for the Treatment of Alcohol Use Disorder
Official Title
"ALCO-VR": Virtual Reality Cue Exposure Therapy for the Treatment of Alcohol Use Disorder.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Completed
Study Start Date
September 15, 2018 (Actual)
Primary Completion Date
June 15, 2021 (Actual)
Study Completion Date
June 15, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Barcelona
Collaborators
Hospital Clinic of Barcelona, Ministry of Health, Spain, Agència de Gestió d'Ajuts Universitaris i de Recerca

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Alcohol-related stimuli emerge as high-risk cues for individuals diagnosed with alcohol use disorder (AUD). Relapse after treatment remains a challenge in AUD. Alcohol craving and anxiety are factors contributing to relapse, even after completion of treatment. The current study aims to test the efficacy of a Virtual Reality Cue-Exposure Therapy (VR-CET) patients diagnosed with severe AUD, who made several failed attempts to cease alcohol drinking. It is expected that VR-CET is more efficient in reducing AUD symptomatology and preventing relapses than treatment-as-usual (TAU). 80 participants will be randomly assigned to experimental or control group. Data regarding alcohol craving and anxiety will be assessed prior to, at the end of and 3, 6 and 12 months after completion of the treatment. The experimental group will receive treatment-as-usual supplemented with 6 sessions of virtual reality cue-exposure therapy (TAU + VR-CET) over the course of five weeks. VR-CET booster sessions consist of exposure to preferred alcoholic beverages and alcohol-related contexts in a VR environment. Throughout the six VR-CET sessions, momentary anxiety and alcohol craving levels will be assessed. The control group will receive only treatment-as-usual (TAU).
Detailed Description
The efficacy of VR Cue Exposure Therapy and Cognitive Behavioral Therapy will be investigated on 80 primarly diagnosed by AUD. Participants will be recruited from Hospital Clínico de Barcelona (Barcelona, Spain). They will be randomly assigned to two booster treatments: treatment-as-usual supplemented with 6 sessions of virtual reality cue-exposure therapy (TAU + VR-CET) versus only treatment as-usual (TAU). Each session will start with filling the questionnaires that will be mentioning below. Secondly, visuo-tactile and visuo-motor stimulation will be induced to participants to get illusory feelings of ownership over the virtual body. Then patients will be choosing their favorite beverages and favorite places to have drinks. During exposure to a specific beverage in VR, participants' olfactory sense will also be stimulated by pouring the beverage onto a cotton and making the participant smell. Virtual Reality-based Cue Exposure Therapy (CET-VR): the intervention will consist of 6 sessions (two per week) lasting approximately 50 minutes. Throughout the sessions, the patient will be exposed to an individualized hierarchy of different VR environments that simulate situations and stimuli related to alcohol consumption. During exposure, the level of craving and anxiety experienced by patients will be assessed using visual analog scales. Once the level of craving has decreased sufficiently (40% of the initial level) in a given situation, it will move to another of greater difficulty to complete the hierarchy. The objective of the intervention is to reduce the craving response of patients in these situations through habituation and extinction processes, so that the generalization of the responses learned during treatment to real situations reduces the risk of relapse. Treatment-as-usual (TAU): All participants received therapy on an individual and group basis. The primary therapeutic goal of TAU was to maintain abstinence from alcohol during and after treatment discharge. The treatment consisted of a combination of pharmacotherapy and psychotherapy. Pharmacotherapy generally included medication such as disulfiram, anxiolytics, and/or antidepressants. Individual and group therapy sessions were based on psychotherapeutic approaches like cognitive-behavioral therapy and motivational interviewing. Weekly groups included facilitated recovery-oriented discussions in an open-group format. The TAU groups met once or twice weekly for 1 hour and 30 minutes. Patients assigned to the TAU condition were administered two assessment sessions with a 4-5-week diference in-between. The initial evaluation session will be approximately one hour. The same evaluation instruments with the same procedure will be implemented in the post-treatment session, once finished either virtual reality or cognitive-behavioral therapy. The eye-tracking and psychophysiological recording instruments will NOT be used during the treatment, but only in the pre- and post-treatment evaluation sessions. In order to evaluate the effectiveness of both interventions in the medium and long term, all participants in the study will be examined in follow-up sessions after 3, 6 and 12 months. Follow-up will consist of self-report evaluation of alcohol craving and anxiety, and maintenance of abstinence (in case of relapse).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment-as-usual supplemented with virtual reality cue-exposure therapy
Arm Type
Experimental
Arm Description
Treatment-as-usual supplemented with virtual reality cue-exposure therapy (TAU + VR-CET).
Arm Title
Treatment-as-usual
Arm Type
Active Comparator
Arm Description
Only treatment-as-usual (TAU)
Intervention Type
Behavioral
Intervention Name(s)
Virtual Reality Cue Exposure Therapy
Intervention Description
Exposure to alcohol-related cues within virtual environments
Intervention Type
Behavioral
Intervention Name(s)
Treatment-as-usual
Intervention Description
Pharmacotherapy and psychotherapy
Primary Outcome Measure Information:
Title
Change in Craving based on AUDIT
Description
Change in Craving levels using the Alcohol Use Disorders Identification Test (AUDIT), with scores ranging from 0 to 40. Higher scores reflect higher levels of craving
Time Frame
from pre-assessment to post-assessment sessions up to 3 weeks
Title
Change in Craving based on MACS
Description
Change in Craving levels using the Multidimensional Alcohol Craving Scale (MACS), with scores ranging from 0 to 60. Higher scores reflect higher levels of craving
Time Frame
from pre-assessment to post-assessment sessions up to 3 weeks
Title
Change in Anxiety
Description
Change in Anxiety levels using the State-Trait Anxiety Inventory (STAI), with scores ranging from 0 to 60. Higher scores reflect higher levels of anxiety
Time Frame
from pre-assessment to post-assessment sessions up to 3 weeks
Other Pre-specified Outcome Measures:
Title
Craving levels during exposure sessions
Description
Visual Analogue Scales from 0-100. Higher scores reflect higher levels of craving
Time Frame
Up to 50 minutes. Baseline (prior to beginning the session), every 20 seconds during the virtual reality session, and at the end of the session
Title
Anxiety levels during exposure sessions
Description
Visual Analogue Scales from 0-100. Higher scores reflect higher levels of anxiety
Time Frame
Up to 50 minutes. Baseline (prior to beginning the session), every 20 seconds during the virtual reality session, and at the end of the session

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with moderate (4-5 diagnostic criteria) or severe (6 or more diagnostic criteria) AUD according to DSM-5 Minimum 3 days abstinence before initial evaluation Exclusion Criteria: severe cognitive impairment that could interfere with comprehension and completion of the task severe psychopathology (e.g. major depression, schizophrenia, dementia) opiate addiction epilepsy severe visual impairments pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José Gutiérrez Maldonado, Prof. Dr.
Organizational Affiliation
University of Barcelona
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitat de Barcelona
City
Barcelona
ZIP/Postal Code
08035
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

"ALCO-VR": Virtual Reality Cue Exposure Therapy for the Treatment of Alcohol Use Disorder

We'll reach out to this number within 24 hrs